Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp Le Coutre, Oliver G. Ottmann, Francis Giles, Dong Wook Kim, Jorge Cortes, Norbert Gattermann, Jane F. Apperley, Richard A. Larson, Elisabetta Abruzzese, Stephen G. O'Brien, Kazimierz Kuliczkowski, Andreas Hochhaus, Francois Xavier Mahon, Giuseppe Saglio, Marco Gobbi, Yok Lam Kwong, Michele Baccarani, Timothy Hughes, Giovanni Martinelli, Jerald P. RadichMing Zheng, Yaping Shou, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds